NCT05583097 (Ultracyt) is a NA clinical trial of Non-selective cytology in Thyroid Cancer, sponsored by Vastra Gotaland Region.

Who is sponsoring NCT05583097?

NCT05583097 is sponsored by Vastra Gotaland Region.

What drugs are being tested in NCT05583097?

Interventions in NCT05583097: Non-selective cytology.

What condition does NCT05583097 study?

NCT05583097 studies Thyroid Cancer, Thyroid Nodule.

Is NCT05583097 still recruiting?

NCT05583097 is currently completed. Last updated 1 April 2025.

Last reviewed 2025-04-01 · How we verify

NCT05583097: Ultracyt

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Ultracyt Study - is EU-TIRADS Useful in Selecting Nodules for Fine Needle Aspiration Cytology?

Completed NA Last updated 1 April 2025

What this trial tests

NA trial testing Non-selective cytology in Thyroid Cancer in 195 participants. Completed in 31 December 2023.

Timeline

15 February 2022

Primary endpoint
20 December 2023

31 December 2023

Quick facts

Lead sponsor	Vastra Gotaland Region
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	195
Start date	15 February 2022
Primary completion	20 December 2023
Estimated completion	31 December 2023
Sites	1 location across Sweden

Drugs / interventions tested

Non-selective cytology

Conditions studied

Thyroid Cancer — all drugs for Thyroid Cancer →
Thyroid Nodule — all drugs for Thyroid Nodule →

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Thyroid Cancer or Thyroid Nodule. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized study evaluating selective fine-needle aspiration cytology based on structured ultrasound using EU-TIRADS versus non-selective ultrasound guided cytology. Primary outcome is frequency of suspicious cytology (Bethesda III-VI) which is expected to be higher in the selective group compared to the non-selective group. Secondary outcome is the frequency of malignancy which is expected to be equal in both groups. However, the investigators do not expect to reach statistical significance for the secondary outcome according to power calculations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other Vastra Gotaland Region trials

Trials by the same sponsor.

NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
NCT07472335 — Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Obse · not yet recruiting
NCT07246577 — The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant C · recruiting
NCT07449338 — Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS) · not yet recruiting
NCT07334340 — Modified vs Standard CDED: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05583097 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vastra Gotaland Region
Last refreshed: 1 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05583097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing